MagicMed Industries' focus is on creating new molecules based on psychedelics, said CEO Dr. Joseph Tucker — but with better attributes.
Those attributes help take molecules from the discovery to the preclinical phase, Tucker said Friday at the virtual Benzinga Cannabis Capital Conference.
A May acquisition agreement with Enveric Biosciences Inc (NASDAQ: ENVB) will help expand MagicMed's efforts to include cannabinoids, he said.
"Now we have a complete end-to-end company from discovery all the way through clinical trials with psychedelics and cannabinoids," Tucker said.
The work would be focused entirely on …